Tesofensine
A serotonin-norepinephrine-dopamine reuptake inhibitor originally researched for Parkinson’s and Alzheimer’s, later studied as a potent appetite suppressant.
What It Is
Tesofensine is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) originally researched as a Parkinson’s and Alzheimer’s adjunct, later studied as a potent appetite suppressant with broader metabolic effects. It is pharmacologically distinct from the GLP-1/GIP/glucagon and amylin-based compounds elsewhere on this page — it works through central neurotransmitter reuptake inhibition rather than gut-hormone receptor activity.
Research and reported effects span weight loss (appetite suppression, increased energy expenditure, increased fat oxidation, reduced cravings) as well as effects tied to its neurotransmitter activity: cognitive and mood effects, and reported changes in libido linked to increased dopamine activity.
Who May Benefit
- Appetite-suppression research where GLP-1/amylin mechanisms haven’t been sufficient or appropriate
- Research contexts also interested in cognitive/mood effects tied to monoamine reuptake inhibition
- Binge-eating-pattern research (per source material)
What to Expect
Tesofensine has a long half-life, and source material indicates one dose per day is sufficient — unlike weekly injectable compounds, this is a daily oral protocol.
Reported effects span both the metabolic (appetite suppression, increased energy, improved blood sugar handling, targeted reduction in abdominal fat) and neurological/psychiatric domains (mood, anxiety, sleep, libido) given its mechanism — which is exactly why its contraindication list is longer and more serious than most other compounds discussed here.
What to Pair It With
Reconstitution
Specific reconstitution figures for this compound weren’t included in the source material. Reconstitution ratios vary by vial size and intended concentration — use a peptide reconstitution calculator and consult your research protocol source before proceeding.
Suggested Research Dosing Strategy
Administration Notes
Oral tablet, no reconstitution required.
Do not use with: pregnancy or nursing; pre-existing cardiovascular disease, uncontrolled hypertension, arrhythmias, or ischemic disease risk; uncontrolled bipolar disorder, uncontrolled depression, schizophrenia, or other serious psychiatric history; recent or current MAOI use; glaucoma; or concurrent use of other serotonergic agents (SSRIs, SNRIs, tricyclic antidepressants, MAOIs).
Research Considerations
Tesofensine’s mechanism — blocking reuptake of three monoamine neurotransmitters simultaneously — is a fundamentally different (and more centrally active) approach than the gut-hormone-receptor mechanisms used by GLP-1/GIP/glucagon/amylin compounds, which is the direct reason for its longer contraindication list.
Its dual research history (neurological adjunct, then repurposed for appetite suppression) is a useful reminder that a compound’s original research intent and its later popular use can diverge significantly — the contraindications from its neurological research history still fully apply to its use here.
Have a specific question about Tesofensine? Chat with Pulse, Signal IQ’s free AI research assistant — ask about mechanisms, stacking, or how it compares to other compounds.